US5487739A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Implantable therapy systems and methods
Assignee: Brown University Research Foundation Inc
•
Filing: 1995-06-02
•
Granted: 1996-01-30
•
Expires: 2015-06-02
Abstract
Abstract Implantable therapy systems are disclosed for the local and controlled delivery of a biologically active factor to the brain, spinal cord and other target regions of a subject suffering from a debilitating condition. The method of the invention involves surgically exposing an insertion site, generally located above a predetermined treatment site (12), in a patient. A cannula (20), having an obturator (30) or dilator (104) positioned therein, is inserted at the insertion site, defining a pathway to the treatment site. In some instances, the cannula can be inserted along the path of a guidewire (102) previously positioned at the treatment site. The cannula (20) is preferably a low friction polymeric material such as polytetrafluoroethylene. The cannula (20) generally has an open proximal end for receiving the obturator (30) or dilator (104), and an open distal end, preferably a tapered end, for delivery of neurologically active factors to the treatment site (12). The obturator (30) is then removed from the cannula (20), and a biocompatible tethered vehicle (40) containing a biologically active material is inserted into the cannula along the passageway. A pusher can be inserted within the cannula, behind the vehicle (40), to position the proximal end of the vehicle at the distal end of the cannula (20b). Once the vehicle (40) is positioned near the distal end of the cannula (20), the cannula is removed from the passageway, followed by the pusher, leaving the vehicle (40) positioned at the treatment site (12).
Inventors
- 👤 Patrick Aebischer
- 👤 Moses Goddard
- 👤 John G. Moldauer
- 👤 Paul J. Mulhauser
- 👤 Anne M. Rathbun
- 👤 Paul R. Sanberg
- 👤 Alfred V. Vasconcellos
- 👤 Nicholas F. Warner
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 10:36
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0087; A61K9/0092; A61B; A61B90/00; A61B90/10; A61F; A61F2/00; A61F2/02; A61F2/022; A61K35/00; A61K35/12; A61K35/55; A61K9/0012; A61K9/0019; A61K9/0024; A61K9/0085; A61M; A61M31/00; A61M31/002; A61M37/00; A61M37/0069; A61M39/00; A61M39/02; A61M39/0208; B; B01; B01J; B01J13/00; B01J13/02; C; C12; C12N; C12N11/00; C12N11/02; C12N11/04; C12N5/00; C12N5/0012; C12N5/06; C12N5/0602; C12N5/0613; C12N5/0614; C12N5/0618; C12N5/0619; C12N5/0676; A61B17/00; A61B17/34; A61B17/3415; A61B17/3478; A61B2090/103; A61K2035/126; A61M2210/00; A61M2210/06; A61M2210/0687; A61M2210/0693; C12N2533/00; C12N2533/30
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
259 words
A system for delivering a biologically active factor to a selected treatment site in a subject, comprising: i) a single cannula adapted for penetration through tissue into a selected position in proximity with the treatment site, having a bore with a substantially smooth interior surface running axially therethrough through which a vehicle may slidably move, an open, proximal end into which the vehicle may be slidably inserted and a distal end having an opening through which the vehicle may slidably move wherein the external diameter and bore diameter are tapered toward the distal tip; ii) an obturator disposable within the cannula to prevent tissue material from entering the distal end of the cannula when it is inserted into tissue; iii) a vehicle which encapsulates the biologically active factor, the vehicle having an outer surface which comprises a biocompatible semipermeable outer membrane through which the biologically active factor may be released into the selected treatment site, and a shape which enables slidable insertion into the proximal end of the cannula, slidable movement along the bore of the cannula, slidable passage through the distal end of the cannula by removal of the cannula from the proximity of the treatment site; and iv) a pusher disposable within the cannula to engage the outer surface of the vehicle, to slidably move the vehicle through the bore, and to hold the vehicle in place at the selected treatment site when the cannula is removed from the proximity of the treatment site, the pusher being removable after the vehicle is positioned at the treatment site.
Claim 2
Independent Claim
259 words
A system for delivering a biologically active factor to a selected treatment site in a subject, comprising: i) a single cannula adapted for penetration through tissue into a selected position in proximity with the treatment site, having a bore with a substantially smooth interior surface running axially therethrough through which a vehicle may slidably move, an open, proximal end into which the vehicle may be slidably inserted and a distal end having an opening through which the vehicle may slidably move wherein the external diameter and bore diameter are tapered toward the distal tip; ii) an obturator disposable within the cannula to prevent tissue material from entering the distal end of the cannula when it is inserted into tissue; iii) a vehicle which encapsulates the biologically active factor, the vehicle having an outer surface which comprises a biocompatible semipermeable outer membrane through which the biologically active factor may be released into the selected treatment site, and a shape which enables slidable insertion into the proximal end of the cannula, slidable movement along the bore of the cannula, slidable passage through the distal end of the cannula by removal of the cannula from the proximity of the treatment site; and iv) a pusher disposable within the cannula to engage the outer surface of the vehicle, to slidably move the vehicle through the bore, and to hold the vehicle in place at the selected treatment site when the cannula is removed from the proximity of the treatment site, the pusher being removable after the vehicle is positioned at the treatment site.
Claim 3
Dependent Claim
130 words
The system of claim 1, further comprising: i) a guidance needle having a lumen running axially therethrough and being insertable into proximity with the treatment site; ii) a guidewire insertable into proximity with the treatment site and able to pass completely through the lumen of the guidance needle; wherein the cannula is adapted to receive the guidewire and wherein the lumen of the guidance needle has a first open end for receiving the guidewire, and a second open end for passage of the guidewire to the treatment site, the guidance needle being fully removable after insertion of the guidewire to the treatment site without disturbing the proximity of the guidewire to the treatment site, and the guidewire being able to guide the insertion of the cannula to the treatment site.
Claim 4
Dependent Claim
41 words
The system of claim 2, further comprising at least one dilator disposable along the guidewire to enlarge a pathway through which the cannula is inserted, the dilator having a dilator bore running axially therethrough and able to pass the guidewire therein.
Claim 5
Dependent Claim
14 words
The system of claim 3, wherein the guidance needle has a beveled, curved tip.
Claim 6
Dependent Claim
54 words
The system of claim 2, further comprising at least one obturator for insertion within and along the lumen of the guidance needle to prevent backfill of materials into the guidance needle during insertion of the guidance needle, the obturator being fully removable after insertion of the guidance needle into proximity with the treatment site.
Claim 7
Dependent Claim
42 words
The system of claim 1, wherein at least a portion of the proximal end of the cannula is transparent to permit monitoring the progress of the vehicle during insertion into the cannula and during passage through the transparent portion of the cannula.
Claim 8
Dependent Claim
47 words
The system of claim 1, wherein the distal end of the cannula is rounded to reduce ancillary tissue damage, and wherein the active factor comprises at least one neuroactive factor selected from the group consisting of peptide neurotransmitters, growth factors, trophic factors, catecholamines, opioid peptides and hormones.
Claim 9
Dependent Claim
36 words
The system of claim 1, wherein the system is adapted for delivering the vehicle into a human spinal region, and wherein the vehicle releases at least one antinociceptive agent useful in a treatment for pain relief.
Claim 10
Dependent Claim
16 words
The system of claim 1, wherein the vehicle encapsulates cells that secrete the biologically active factor.
Claim 11
Dependent Claim
14 words
The system of claim 9, wherein the encapsulated cells comprise adrenal medullary chromaffin cells.
Claim 12
Dependent Claim
45 words
The system of claim 9, wherein the distal end of the cannula is rounded to reduce ancillary tissue damage, and wherein the active factor comprises a neuroactive factor selected from the group consisting of peptide neurotransmitters, growth factors, trophic factors, catecholamines, opioid peptides and hormones.
Claim 13
Dependent Claim
23 words
The system of claim 1, wherein the vehicle further comprises an impermeable protective barrier material which coats a portion of the outer membrane.
Claim 14
Dependent Claim
17 words
The system of claim 1, wherein the cannula is constructed from material comprising a low friction polymer.
Claim 15
Dependent Claim
10 words
The system of claim 13, wherein the polymer comprises polytetrafluoroethylene.
Claim 16
Dependent Claim
22 words
The system of claim 1, wherein the active factor comprises at least one antinociceptive agent useful in a treatment for pain relief.
Claim 17
Dependent Claim
20 words
The system of claim 1, wherein the cannula is flexible for the delivery of the vehicle through a curved pathway.
Claim 18
Independent Claim
300 words
A method for delivering a biologically active factor to a selected treatment site in a subject, comprising: i) surgically opening an insertion site located near the selected treatment site; ii) inserting a single cannula adapted for penetration through tissue and an obturator disposed therein into the insertion site and placing the distal end of the cannula at a selected position in proximity with the treatment site, the cannula having a bore with a substantially smooth surface running axially therethrough through which a vehicle may slidably move, an open, proximal end into which the vehicle may be slidably inserted and a distal end having an opening through which the vehicle may slidably move wherein the external diameter an bore diameter are tapered toward the distal tip; iii) removing the obturator from the cannula; iv) introducing within the bore of the cannula a vehicle which encapsulates the biologically active factor, the vehicle having an outer surface which comprises a biocompatible semipermeable outer membrane through which the biologically active factor may be released into the selected treatment site, and a shape which enables slidable insertion into the proximal end of the cannula, slidable movement along the bore of the cannula, slidable passage through the distal end of the cannula by removal of the cannula from the proximity of the treatment site; v) delivering the vehicle to the distal end of the cannula with a pusher disposable within the cannula to engage the outer surface of the vehicle, to slidably move the vehicle through the bore, and to hold the vehicle in place at the selected treatment site when the cannula is removed from the proximity of the treatment site; vi) removing the cannula from the tissue, while leaving the vehicle inserted at the treatment site; and vii) removing the pusher from the tissue.
Claim 19
Independent Claim
300 words
A method for delivering a biologically active factor to a selected treatment site in a subject, comprising: i) surgically opening an insertion site located near the selected treatment site; ii) inserting a single cannula adapted for penetration through tissue and an obturator disposed therein into the insertion site and placing the distal end of the cannula at a selected position in proximity with the treatment site, the cannula having a bore with a substantially smooth surface running axially therethrough through which a vehicle may slidably move, an open, proximal end into which the vehicle may be slidably inserted and a distal end having an opening through which the vehicle may slidably move wherein the external diameter an bore diameter are tapered toward the distal tip; iii) removing the obturator from the cannula; iv) introducing within the bore of the cannula a vehicle which encapsulates the biologically active factor, the vehicle having an outer surface which comprises a biocompatible semipermeable outer membrane through which the biologically active factor may be released into the selected treatment site, and a shape which enables slidable insertion into the proximal end of the cannula, slidable movement along the bore of the cannula, slidable passage through the distal end of the cannula by removal of the cannula from the proximity of the treatment site; v) delivering the vehicle to the distal end of the cannula with a pusher disposable within the cannula to engage the outer surface of the vehicle, to slidably move the vehicle through the bore, and to hold the vehicle in place at the selected treatment site when the cannula is removed from the proximity of the treatment site; vi) removing the cannula from the tissue, while leaving the vehicle inserted at the treatment site; and vii) removing the pusher from the tissue.
Claim 20
Dependent Claim
165 words
The method of claim 17, further comprising before a step of inserting the cannula, i) inserting a guidance needle having a lumen running axially therethrough into proximity with the treatment site; ii) inserting a guidewire through the lumen of the inserted needle and into proximity with the treatment site, the guidewire able to pass completely through the lumen of the guidance needle; and iii) removing the guidance needle from the treatment site without disturbing the proximity of the guidewire to the treatment site; wherein the cannula is adapted to receive the guidewire and wherein the lumen of the guidance needle has a first open end for receiving the guidewire, and a second open end for passage of the guidewire to the treatment site, the guidance needle being fully removable after insertion of the guidewire to the treatment site without disturbing the proximity of the guidewire to the treatment site, and the guidewire being able to guide the insertion of the cannula to the treatment site.
Claim 21
Dependent Claim
60 words
The method of claim 18, further comprising disposing, after removing the guidance needle, at least one dilator along the guidewire and towards the treatment site to enlarge a pathway through which the cannula is inserted, the dilator having a dilator bore running axially therethrough and able to pass the guidewire therein, the dilator being removed before the cannula is removed.
Claim 22
Dependent Claim
73 words
The method of claim 18, further comprising, before a step of inserting the guidewire, disposing at least one obturator in the lumen of the guidance needle, the obturator of the type designed for insertion within and along the lumen of the guidance needle to prevent backfill of materials into the guidance needle during insertion of the guidance needle into proximity with the treatment site, the obturator being removed before the guidewire is inserted.
References Cited (Backward Citations)
US3093831A
Cited
US3583387A
Cited
US3911911A
Cited
US3640269A
Cited
US4241187A
Cited
US4391909A
Cited
US4352883A
Cited
US4298002A
Cited
US4309776A
Cited
US4451253A
Cited
US4378016A
Cited
US4402694A
Cited
WO1984000304A1
Cited
US4479796A
Cited
GB2130916A
Cited
EP0147939A2
Cited
US4973304A
Cited
US4686098A
Cited
FR2564734A1
Cited
US4578057A
Cited
US4619644A
Cited
US4960415A
Cited
EP0213908A2
Cited
US4902295A
Cited
WO1987003802A2
Cited
US4850975A
Cited
WO1988010103A1
Cited
EP0304700A1
Cited
US4941874A
Cited
US4931056A
Cited
US4767400A
Cited
US5106627A
Cited
US4892538A
Cited
WO1989004655A1
Cited
US4994027A
Cited
US5004457A
Cited
US4976670A
Cited
WO1991000119A1
Cited
US5125888A
Cited
US5292515A
Cited
US5139486A
Cited
WO1992013501A1
Cited
US5158544A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-01-29 | 1999-07-31 | 2000-01-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-01-29 | 2003-07-31 | 2004-01-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-01-29 | 2007-07-31 | 2008-01-30 | $7700.00 | Window Closed / Lapsed |